全部分类

其他报告

(10w+ 篇文档)

3金币 CMIC：2020年快速变化的研发流程如何放大可适应的CRO的重要性白皮书（英文版）.PDF

Major advances in our understanding of the causes of once-untreatable diseases have reshaped the global drug development pipeline over the past decade, paving the way for better health outcomes for many millions of people. To realize these emergin...

内容提供方：外唐用户 | 2025-08-01 发布 | 1.1MB | 9 页
3金币 CMIC：C-PRESS公共关系杂志-第16卷（英文版）.PDF

Nakamura Since the end of the Second World War, the average lifetime has increased rapidly in Japan and the Japanese have the longest life expectancy in the world. Establishment of world-class, excellent systems, such as a universal health insuran...

内容提供方：外唐用户 | 2025-08-01 发布 | 9.34MB | 7 页
8金币 CMIC：2020年强化的CMO关系为赞助商扩展机会报告（英文版）.PDF

Key strategies that can lead to a win-win relationship include a relationshipon a solid foundation, softfactors, and project managementexcellence. This article discussesthese strategies as well as FDAguidelines on quality agreementsfor the contrac...

内容提供方：外唐用户 | 2025-08-01 发布 | 4.66MB | 30 页
5金币 CMIC：2020年早期药物开发报告（英文版）.PDF

While pivotal clinical trials remain critical to securing the approvalsrequired for the launch of new drugs, it is interesting and also encouraging to observe acommon thread running through some recent regulatory and policy discussions.
That...

内容提供方：外唐用户 | 2025-08-01 发布 | 5.87MB | 18 页
5金币 CMIC：2013年全球合同研究组织委员会（GCC）关于已使用样品稳定性（ISS）的建议白皮书（英文版）.PDF

The topic of Incurred Sample Stability (lSS) has generated considerable discussion within thebioanalytical community in recent years. The subject was an integral part of the 7" annualWorkshop on Recent lssues in Bioanalysis (WRlB) held in Lon...

内容提供方：外唐用户 | 2025-08-01 发布 | 5.13MB | 11 页
5金币 CMIC：2011年GCC关于生物分析方法稳定性对联合给药和联合配方药物影响的建议白皮书（英文版）.PDF

In 2010, the global bioanalytical community learned of regulatory agency concern of the potential for co-administered compounds present in a bioanalytical matrix to impact the stability of analytes subject to bioanalytical measurement. This pertai...

内容提供方：外唐用户 | 2025-08-01 发布 | 612.63KB | 11 页
5金币 CMIC：2019年亚洲临床试验报告（英文版）.PDF

there is no longer any excuse not toinclude japan as an integral part of anyglobal clinical-development programfor either pharmaceuticals or medicaldevices. With a more receptive climatefor both starting and running trials, an improvedinfrastructu...

内容提供方：外唐用户 | 2025-08-01 发布 | 2.45MB | 20 页
8金币 CMIC：2017年全球临床试验的变革之面：亚太地区成为专业生物制药的理想目的地白皮书（英文版）.PDF

The contract research organization (CRO) marketin the Asia-Pacific (APAC) region is the fastest-growing in the world, with revenue expected toincrease at a 20% compound annual growth rate(CAGR) from 2016 to 202l compared with therest of the world&...

内容提供方：外唐用户 | 2025-08-01 发布 | 1.49MB | 32 页
3金币 CMIC：2018年如何在日本成功进行临床试验白皮书（英文版）.PDF

There is no longer any excuse not to include Japan as an integral part of any globalclinical-development program for either pharmaceuticals or medical devices. With amore receptive climate for both starting and running trials, an improved infrastr...

内容提供方：外唐用户 | 2025-08-01 发布 | 227.32KB | 9 页
5金币 CMIC：2019年药物开发与制造：挑战与机遇报告（英文版）.PDF

QUESTION :In 2007, CMIc acquired a manufacturingplant in New Jersey. That early acquisition became CMICCMO USA, a contract service provider for oral solid drugmanufacturing. What has changed for the Us part of thecompany?
MAKOTO MATSUKAWA: T...

内容提供方：外唐用户 | 2025-08-01 发布 | 877.8KB | 15 页